



# Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

June 17, 2020

Corporate Relationship Department  
The BSE Ltd.  
Dalal Street, Fort  
**Mumbai 400 001.**  
Scrip Code: 524816

Manager – Listing  
National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
**Bandra (E) Mumbai 400 051.**  
Scrip Code: NATCOPHARM

Dear Sir,

**Sub: - Outcome of Board Meeting**

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

Sl. No.	Particulars
1	Audited Financial Results (Standalone and Consolidated) for the year ended 31 <sup>st</sup> March, 2020 and financial results for the quarter ended 31 <sup>st</sup> March, 2020 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) along with Auditor’s Report(s) of the Statutory Auditors. Please find enclosed a copy of the same for your information and a declaration as required under Listing Regulations.
2	Declaration of fourth (4 <sup>th</sup> ) interim dividend of Rs.1/- per equity share of Rs.2/- each for the financial year 2019-20. The date for taking a record of its shareholders eligible for the purpose of payment of fourth (4 <sup>th</sup> ) interim dividend <b>i.e. Record date is fixed for June 29, 2020.</b> The said interim dividend will be paid on or before <b>July 5, 2020.</b>
3	Reappointed the following working Directors of the Company for a period of one year from 1st April, 2020 to 31 <sup>st</sup> March, 2021 subject to the approve: l of the members of the Company at the ensuing Annual General Meeting to be held in the calendar year 2020 and brief profiles of them are enclosed as <b>Annexure 1</b> herewith. (i) Sri V.C. Nannapaneni, DIN: 00183315, Chairman & Managing Director (ii) Sri Rajeev Nannapaneni, DIN: 00183872, Vice Chairman & CEO (iii) Sri P.S.R.K. Prasad, DIN: 07101140, Director & Executive Vice President (CES) and (iv) Dr. D. Linga Rao, DIN: 07088404, Director & President (Technical Affairs) We hereby confirm that all the above mentioned reappointed Directors are not debarred from holding the office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such authority.
4	Notice of 37 <sup>th</sup> Annual General Meeting (AGM) was approved and Board had authorised Sri V C Nannapaneni, Chairman and Managing Director for finalizing the date, time, venue, Book Closure dates and mode of conducting of Annual General Meeting for the financial year 2019-20
5	The Board of Directors have approved the investment and authorized Sri V.C. Nannapaneni, Chairman and Managing Director and Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer to finalise the terms and conditions of the proposed investments not exceeding US \$ 7.50 Lakhs ( Seven Lakhs fifty thousand dollars) in AACT, Inc., USA. The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the aforesaid investments is enclosed as Annexure //

*M. Anandarama*



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

--2--

We are also updating the financial results on the website of the Company.

Please find enclosed a disclosure as per Regulation 33(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, declaration in respect of Audit Reports with unmodified opinion for the Financial year ended March 31, 2020.

Meeting commenced at 12.20 p.m. and concluded at 1.25 p.m.

This is for your information and records.

Thanking you,

Yours faithfully,

For NATCO Pharma Limited

*M Adinarayana*

M Adinarayana

Company Secretary &

Vice President (Legal & Corp. Affairs)

FCS: 3808

Encl: as above.